ERG and prostate carcinoma: Recently the male sex hormone androgen has been demonstrated to promote the recruitment of androgen receptor (AR) and topoisomerase II beta (TOP2B) to genomic breakpoints induced at androgen responsive genes including TMPRSS2: ERG fusion, the most common fusion detected in prostate cancer [4].